PL2885641T3 - Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi - Google Patents
Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwiInfo
- Publication number
- PL2885641T3 PL2885641T3 PL13830006T PL13830006T PL2885641T3 PL 2885641 T3 PL2885641 T3 PL 2885641T3 PL 13830006 T PL13830006 T PL 13830006T PL 13830006 T PL13830006 T PL 13830006T PL 2885641 T3 PL2885641 T3 PL 2885641T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- predicting risk
- developing hypertension
- hypertension
- developing
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683956P | 2012-08-16 | 2012-08-16 | |
| EP13830006.6A EP2885641B1 (en) | 2012-08-16 | 2013-08-16 | Methods for predicting risk of developing hypertension |
| PCT/US2013/055417 WO2014028875A1 (en) | 2012-08-16 | 2013-08-16 | Methods for predicting risk of developing hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2885641T3 true PL2885641T3 (pl) | 2018-04-30 |
Family
ID=50100476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13830006T PL2885641T3 (pl) | 2012-08-16 | 2013-08-16 | Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9523696B2 (pl) |
| EP (2) | EP3282258A1 (pl) |
| JP (3) | JP6298466B2 (pl) |
| CN (2) | CN107478841A (pl) |
| AU (2) | AU2013302451B2 (pl) |
| CA (1) | CA2882133A1 (pl) |
| DK (1) | DK2885641T3 (pl) |
| ES (1) | ES2656897T3 (pl) |
| HK (1) | HK1250782A1 (pl) |
| IN (1) | IN2015DN01259A (pl) |
| MX (2) | MX358541B (pl) |
| NO (1) | NO2983845T3 (pl) |
| PL (1) | PL2885641T3 (pl) |
| RU (2) | RU2019107598A (pl) |
| SG (2) | SG11201501200XA (pl) |
| WO (1) | WO2014028875A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| SI2336359T1 (sl) | 2002-05-09 | 2016-08-31 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 kot marker kardiovaskularne bolezni |
| ES2646142T3 (es) | 2006-04-24 | 2017-12-12 | Critical Care Diagnostics, Inc. | Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2 |
| PL2482078T3 (pl) | 2006-05-01 | 2016-08-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| HUE039963T2 (hu) | 2008-04-18 | 2019-02-28 | Critical Care Diagnostics Inc | Súlyos káros szívesemények rizikójának elõrejelzése |
| HUE027760T2 (en) | 2010-04-09 | 2016-11-28 | Critical Care Diagnostics Inc | Soluble human ST-2 antibodies and assays |
| US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| CN103796669B (zh) | 2011-07-18 | 2016-11-09 | 重症监护诊断股份有限公司 | 治疗心血管疾病和预测运动疗法功效的方法 |
| JP6302896B2 (ja) | 2012-05-18 | 2018-03-28 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法 |
| WO2014026085A1 (en) * | 2012-08-09 | 2014-02-13 | Smith & Nephew, Inc. | Intra-operatively adjustable cutting guide |
| AU2013302451B2 (en) | 2012-08-16 | 2019-01-17 | Critical Care Diagnostics, Inc. | Methods for predicting risk of developing hypertension |
| SG10201608854TA (en) | 2012-08-21 | 2016-12-29 | Critical Care Diagnostics Inc | Multimarker risk stratification |
| CA2961340C (en) | 2014-09-26 | 2023-10-17 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| RU2677611C1 (ru) * | 2018-04-16 | 2019-01-17 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда |
| US11551817B2 (en) | 2020-01-14 | 2023-01-10 | International Business Machines Corporation | Assessing unreliability of clinical risk prediction |
| PH12022552371A1 (en) | 2020-03-13 | 2023-12-18 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
| US20220218292A1 (en) * | 2021-01-14 | 2022-07-14 | Apple Inc. | User interfaces for monitoring health |
| RU2767266C1 (ru) * | 2021-05-27 | 2022-03-17 | Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) | Способ прогнозирования однолетнего риска неблагоприятных сердечно-сосудистых событий у мужчин после декомпенсации хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка сердца и синдромом обструктивного апноэ во сне |
| CN114350670B (zh) * | 2022-03-18 | 2022-06-14 | 北京市心肺血管疾病研究所 | 特异性识别可溶性st2蛋白的核酸适配体及其应用 |
| CN115188465B (zh) * | 2022-06-27 | 2025-09-26 | 深圳技术大学 | 急性加重的预测方法及装置、电子设备和存储介质 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070817A1 (en) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| CN1613012A (zh) * | 2001-11-05 | 2005-05-04 | 布赖汉姆妇女医院 | 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记 |
| SI2336359T1 (sl) | 2002-05-09 | 2016-08-31 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 kot marker kardiovaskularne bolezni |
| US20050250156A1 (en) | 2003-10-31 | 2005-11-10 | Shebuski Ronald J | Detection of acute myocardial infarction biomarkers |
| CA2587601C (en) * | 2004-12-03 | 2017-11-07 | Rhode Island Hospital | Diagnosis and treatment of alzheimer's disease |
| ES2646142T3 (es) * | 2006-04-24 | 2017-12-12 | Critical Care Diagnostics, Inc. | Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2 |
| US20090305265A1 (en) | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PL2482078T3 (pl) | 2006-05-01 | 2016-08-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| PL2019965T3 (pl) | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics Inc | Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego |
| US8147817B2 (en) * | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| GB0703514D0 (en) * | 2007-02-23 | 2007-04-04 | Univ Ulster | Use of riboflavin |
| EP2147115A4 (en) | 2007-04-16 | 2010-05-05 | CARDIOBIOINDEX / CARDIOBIOSCORE AND THE USE OF THE SPOKING PROTEOME IN CARDIOVASCULAR DIAGNOSTICS | |
| ATE533061T1 (de) * | 2007-08-03 | 2011-11-15 | Brahms Gmbh | Verfahren zur diagnose bakterieller infektionen |
| HUE039963T2 (hu) | 2008-04-18 | 2019-02-28 | Critical Care Diagnostics Inc | Súlyos káros szívesemények rizikójának elõrejelzése |
| ES2795003T3 (es) * | 2008-10-07 | 2020-11-20 | Brahms Gmbh | Biomarcador para la predicción de los primeros eventos adversos |
| EP2470910B1 (en) * | 2009-08-28 | 2017-01-11 | B.R.A.H.M.S GmbH | Procalcitonin for the prognosis of adverse events |
| HUE027760T2 (en) | 2010-04-09 | 2016-11-28 | Critical Care Diagnostics Inc | Soluble human ST-2 antibodies and assays |
| GB201013151D0 (en) * | 2010-08-04 | 2010-09-22 | Isis Innovation | Diagnostic method |
| US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| CN103796669B (zh) * | 2011-07-18 | 2016-11-09 | 重症监护诊断股份有限公司 | 治疗心血管疾病和预测运动疗法功效的方法 |
| US20130157290A1 (en) * | 2011-12-16 | 2013-06-20 | Yves Levy | Soluble st2 as a marker for disease |
| JP6302896B2 (ja) * | 2012-05-18 | 2018-03-28 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法 |
| AU2013302451B2 (en) | 2012-08-16 | 2019-01-17 | Critical Care Diagnostics, Inc. | Methods for predicting risk of developing hypertension |
| SG10201608854TA (en) * | 2012-08-21 | 2016-12-29 | Critical Care Diagnostics Inc | Multimarker risk stratification |
| US20150199491A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800333S1 (en) * | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800332S1 (en) * | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2013
- 2013-08-16 AU AU2013302451A patent/AU2013302451B2/en not_active Ceased
- 2013-08-16 SG SG11201501200XA patent/SG11201501200XA/en unknown
- 2013-08-16 CN CN201710532173.1A patent/CN107478841A/zh active Pending
- 2013-08-16 MX MX2015002061A patent/MX358541B/es active IP Right Grant
- 2013-08-16 CN CN201380052763.4A patent/CN104737023B/zh not_active Expired - Fee Related
- 2013-08-16 US US13/969,116 patent/US9523696B2/en active Active
- 2013-08-16 JP JP2015527668A patent/JP6298466B2/ja not_active Expired - Fee Related
- 2013-08-16 MX MX2018010151A patent/MX382403B/es unknown
- 2013-08-16 EP EP17191053.2A patent/EP3282258A1/en not_active Withdrawn
- 2013-08-16 RU RU2019107598A patent/RU2019107598A/ru unknown
- 2013-08-16 DK DK13830006.6T patent/DK2885641T3/da active
- 2013-08-16 SG SG10201704311VA patent/SG10201704311VA/en unknown
- 2013-08-16 ES ES13830006.6T patent/ES2656897T3/es active Active
- 2013-08-16 RU RU2015108959A patent/RU2683026C2/ru active
- 2013-08-16 PL PL13830006T patent/PL2885641T3/pl unknown
- 2013-08-16 WO PCT/US2013/055417 patent/WO2014028875A1/en not_active Ceased
- 2013-08-16 EP EP13830006.6A patent/EP2885641B1/en not_active Not-in-force
- 2013-08-16 CA CA2882133A patent/CA2882133A1/en not_active Abandoned
-
2014
- 2014-04-10 NO NO14716337A patent/NO2983845T3/no unknown
-
2015
- 2015-02-16 IN IN1259DEN2015 patent/IN2015DN01259A/en unknown
- 2015-09-08 HK HK18110132.8A patent/HK1250782A1/en unknown
-
2016
- 2016-12-19 US US15/382,810 patent/US10041957B2/en not_active Expired - Fee Related
-
2018
- 2018-02-23 JP JP2018030232A patent/JP6757757B2/ja not_active Expired - Fee Related
- 2018-08-03 US US16/054,378 patent/US20180335437A1/en not_active Abandoned
-
2019
- 2019-04-15 AU AU2019202597A patent/AU2019202597A1/en not_active Abandoned
-
2020
- 2020-08-31 JP JP2020145790A patent/JP2020196757A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201501200XA (en) | Methods for predicting risk of developing hypertension | |
| GB201102014D0 (en) | Method for predicting risk of developing cancer | |
| EP2686689A4 (en) | METHODS OF PREDICTING RISK OF UNDESIRABLE CLINICAL RESULT | |
| EP2702513A4 (en) | DETERMINATION OF RECOMMENDATION DATA | |
| EP2717100A4 (en) | TONER | |
| EP2710430A4 (en) | Toner | |
| PL2825719T3 (pl) | Sposób obsługi odwiertów | |
| EP2717099A4 (en) | TONER | |
| EP2710432A4 (en) | Toner | |
| EP2691815A4 (en) | TONER | |
| EP2710431A4 (en) | TONER | |
| EP2794330A4 (en) | METHOD AND MODULE FOR DETERMINING AT LEAST ONE REFERENCE VALUE | |
| DK2879615T3 (da) | Fremgangsmåde til at bestemme sandsynlighed for brunst | |
| PL2715352T3 (pl) | Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml) | |
| EP2753982A4 (en) | TONER | |
| BR112015002542A2 (pt) | método de caracterização de um objeto | |
| GB201104556D0 (en) | Biomarkers | |
| GB2510539B (en) | Biomarkers of cancer | |
| AP2014007806A0 (en) | Method for floating | |
| GB201215942D0 (en) | Method of treatent | |
| SG11201502998UA (en) | Methods and kits for increasing or predicting oil yield | |
| ZA201503833B (en) | Method of hemoglobin-f determination | |
| EP2780766A4 (en) | DEVICES FOR QUANTIFYING TEMPORARY TIME | |
| ZA201400950B (en) | Method for predicting risk of hypertension associated with anti-angiogenesis therapy | |
| GB201118778D0 (en) | Biomarker method |